Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (February 2024)
40 slides from Immunome's investor presentation, Feb 8, 2024
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation February 8, 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Long-Term Corporate Vision Strong Foundation for Long-Term Success • Experienced, successful leadership team • Develop first-in-class and best-in-class oncology therapies • Signed definitive purchase agreement for AL102, a Phase 3 asset for the treatm
Slide 4: Recent Business Development Activity Expands Pipeline and Toolbox
Recent Business Development Activity Expands Pipeline and Toolbox With Moderate Investment • Exclusive license of ADC assets • Purchase of AL102, a Phase 3 asset for • Purchase of assets related to over 25 treatment of desmoid tumors preclinical antibodies • Preclinical ROR1 ADC with best-in- class
Slide 5: Pipeline Overview
Pipeline Overview Mechanism of Development Candidate Discovery IND-Enabling Phase 1 Phase 2 Phase 3 Next Milestone Action Candidate Gamma Secretase Close of Asset Acquisition AL102 Inhibitor Phase 3 Full Enrollment IND Submission Undisclosed FAP RLT 1Q25 IND Submission IM-10211 ROR1 ADC 1Q25 Anti-IL
Slide 6: ADC Strategy
ADC Strategy IMMUNOME 6
Slide 7: Target-Driven Development For the Next Generation of ADCs
Target-Driven Development For the Next Generation of ADCs Immunome Approach Systematic Development Through Clinical Proof of Concept • Focus on oncology indications with high unmet need Optimization for binding & internalization • Identify novel or underexplored targets that are suitable for ADCs an
Slide 8: ADC Activity is Concentrated in a Small Number of Targets
ADC Activity is Concentrated in a Small Number of Targets Top 10 Targets Account for 54% of Active Clinical ADC Downsides of Pursuing Most Popular Targets Programs • Limitations of existing drugs may be difficult to overcome Approved ADC • Performance of current drugs may be limited by Active Clinic
Slide 9: Systematically Evaluate Novel Targets for First-in-Class ADC Potential
Systematically Evaluate Novel Targets for First-in-Class ADC Potential Targets are evaluated for differential tumor expression and Sources of Novel Targets and additional considerations Antibodies Solid Tumor ADCs Immunome Discovery Tivdak Platform Trodelvy >30 identified targets Tumor Expression El
Slide 10: Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs
Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs Proprietary ADC Payload HER2 ADC Constructed with IMNM Proprietary Payload Outperforms Enhertu in JIMT-1 Breast Cancer Model • Camptothecin derivative/TOPO1 inhibitor • Same class as Enhertu payload deruxtecan (DXd) 3000 Vehiclec
Slide 11: Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors
Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors $175m Derivative Payload) Enhertu (With Camptothecin ADCs Containing Camptothecins Achieve Higher DARs and Higher Clinical Doses Outperforms Kadcyla in Breast Cancer3 Progression-Free Survival 12 Clinical Doses of Selected ADCs
Slide 12: Strong Demand for ADCs Provides Strategic Flexibility
Strong Demand for ADCs Provides Strategic Flexibility Opportunities to Transact at Value Inflection Points Recent ADC Transactions $170 million $4 billion upfront $2 billion upfront3 total1 $1.5 billion+ $22 billion in milestones in milestones5 $43 billion acquisition7 $175 million $85 million upfro
Slide 13: AL102
AL102 Subject to closing Ayala Transaction IMMUNOME 13
Slide 14: High Unmet Need for Patients with Desmoid Tumors
High Unmet Need for Patients with Desmoid Tumors Desmoid Tumors Are Debilitating, Painful, and Gamma Secretase Inhibitors For Treatment of Aggressive Desmoid Tumors ~1,000-1,650 ~5,500-7,000 • Gamma secretase inhibitors (GSIs) block the NOTCH pathway, a driver of desmoid tumors Patients diagnosed Ac
Slide 15: AL102 Data Shows Superiority to Nirogacestat Across All Measures of Response
AL102 Data Shows Superiority to Nirogacestat Across All Measures of Response ORR by RECIST • AL102 is being evaluated as an oral, AL102 1.2mg QD1 once-daily GSI for the treatment of Evaluable Median ToT 16.6 months 75% ITT desmoid tumors Nirogacestat 150mg BID2,3 64% Median ToT 20.6 months • Phase 2
Slide 16: Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class
Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class IMMUNOME 16
Slide 17: RINGSIDE study design: Phase 3
RINGSIDE study design: Phase 3 Crossover has no observed impact on statistical analysis of primary endpoint IMMUNOME 17
Slide 18: Immunome Discovery Platform
Immunome Discovery Platform IMMUNOME 18
Slide 19: Antibody and Target Discovery Engine
Antibody and Target Discovery Engine Harnessing the Immune System to Inform the Next Generation of Cancer Therapy Patient responses unveil novel disease targets 01 02 03 04 Patients with cancer Memory B cells are Antibodies are selected Novel antibody-target generate memory B cells isolated, and imm
Slide 20: Immunome Approach Identifies Both Validated and Novel Cancer Targets
Immunome Approach Identifies Both Validated and Novel Cancer Targets Identification of Clinically Validated Cancer Immunome Technology Enhances Power Targets Validates Immunome Approach of Antibody Screens • Memory B-cell response generated across course of disease ‒ Competitor B-cell platforms rest
Slide 21: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligible for additional payments up to: ‒ $70M platform access payments (in additi
Slide 22: Programs: ROR1 ADC
Programs: ROR1 ADC IMMUNOME 22
Slide 23: ROR1 Is a Clinically Validated ADC Target
ROR1 Is a Clinically Validated ADC Target MK-2140 Objective Response Rate In Three Pretreated Lymphoma Indications ROR1 • Receptor with oncofetal expression pattern1 • Little or no expression in healthy tissue 60% • Expressed on solid and liquid tumors 50% 14% PR CR 12% 40% MK-2140 • MK-2140 (former
Slide 24: Significant Opportunity for ROR1 in Solid Tumors
Significant Opportunity for ROR1 in Solid Tumors Potential ROR1 indications include ROR1 target biology presents challenges to diseases with large patient population developing a successful ADC for ROR1 and high unmet need positive solid tumors • Moderate to low expression levels • Slow internalizat
Slide 25: IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index
IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index Name Linker / DAR Payload Development Status Zilovertamab Vedotin (MK-2140 / VLS-101) MMAE: Tubulin Inhibitor Phase 2 completed; no MC-VC-PAB O O Et OH further updates Cysteine conjugation H H O N N N H O O O N N S H Cleavable throu
Slide 26: IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model
IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model IM-1021 Inhibits Tumor Growth in MDA-MB-468 Model No Weight Loss Observed (Triple Negative Breast Cancer) 1200 Vehicle qw × 3 30 Vehicle ATX875-1-5379 (2.5 mg/kg qw×3) IM-1021 2.5 mg/kg Tumor Volume (mm3) ATX875-1-5379 (5.0 mg/kg qw×3) 20
Slide 27: Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies
Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies Across Multiple Indications Solid tumor expansion Indications including NSCLC, breast cancer, prostate cancer, pancreatic Pivotal studies as indicated cancer, and gastric cancer1 Rapid dose escalation in • Compel
Slide 28: Programs: FAP RLT
Programs: FAP RLT IMMUNOME 28
Slide 29: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with FAP imaging shows high expression across Pan-Cancer Potential 15 distinct tumor types • Fibroblast Activation Protein (FAP) is a cell surface protease with low expression in normal tissue • FAP is overexpressed on cancer-associated fibroblasts, the most common tumo
Slide 30: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Immunome Approach Designed and Example Proven structure used by Systematically Screened Pluvicto and Lutathera to Optimized linker deliver Lu-177 isotope Structure: reduces non- specific uptake Chelator FAP Ligand Linker Immunome has systematically select
Slide 31: Incorporating Albumin Binders into RLTs Improves In Vivo PK Profile
Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile and Biodistribution Total Absorbed Dose Rat IV PK 600 100000 Albumin Binding Albumin Binding Weak Weak 10000 500 Moderate concentration Moderate Strong Plasmaconcentration 1000 400 Strong (ng/mL) (ng/mL) mGy/MBq 100
Slide 32: Developing 177Lu-FAP Candidates with Best-in-Class Potential
Developing 177Lu-FAP Candidates with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG Model 177 No Weight Loss Observed Stab Characteristics Potential Best-in-Class 177 Lu-Mi-003 Radiotherapy in U87MG tumors Lu-Mi-003 Radiotherapy in
Slide 33: Programs: Anti-IL-38 Immunotherapy
Programs: Anti-IL-38 Immunotherapy IMMUNOME 33
Slide 34: IL-38 Is an Immunosuppressive Cytokine with I/O Potential
IL-38 Is an Immunosuppressive Cytokine with I/O Potential IL-38 Function: Inhibits pro-inflammatory IL-36/IL-36R pathway1 Scientific Rationale: Downregulation of IL-38 promotes innate immune activation • IL-38 knockout mice exhibit increased pro-inflammatory cytokine levels2 and delayed tumor growth
Slide 35: Poor Survival for Cancer Patients with Tumors Expressing High IL-38
Poor Survival for Cancer Patients with Tumors Expressing High IL-38 Reduced Immune Cell Infiltration in IL-38 High Tumors Poor Overall Survival in IL-38 High Lung Cancer Kaplan-Meier curves according to IL-38 expression in patients with primary lung adenocarcinoma IL-38 IHC Stain Intensity Low Mediu
Slide 36: IM-4320: Platform-Derived, Potential First-in-Class Anti-IL-38 Antibody
IM-4320: Platform-Derived, Potential First-in-Class Anti-IL-38 Antibody Inhibits IL-38-mediated immunosuppression IM-4320 Selectively Binds IL-38 IM-4320 Inhibits IL-38 Binding IM-4320 Inhibits Tumor Growth in Mice 100 5000 1st dose IL-38 2000 Vehicle SEM(mm3) (mm ) 80 3 4000 Anti-CTLA4 - 10 mg/kg I
Slide 37: IP, Business Development, and Leadership
IP, Business Development, and Leadership IMMUNOME 37
Slide 38: Prosecuting a Multi-Layered IP Strategy
Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of November 2023 • Covers Immunome’s proprietary PLATFORM & DISCOVERY antibody sequences • Platform technologies and • Covers proprietary targeting discovery engin
Slide 39: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) President & Chief • Grew company to $2B+ revenue (2022) leading to $43B acquisition Executive Officer • Led development of 4 FDA-approved therapeutics • Raised ov
Slide 40: Building the Foundation of a Premier Targeted Oncology Company
Building the Foundation of a Premier Targeted Oncology Company • Experienced management team with headquarters in Bothell, WA • Signed definitive purchase agreement for AL102, a Phase 3 asset for the treatment of desmoid tumors1 • Three programs with best-in-class or first-in-class potential and IND